Tags

Type your tag names separated by a space and hit enter

Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
Clin Pharmacol Ther. 2007 Dec; 82(6):726-33.CP

Abstract

Thirty-two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1 week. Subjects with the SLCO1B1 c.521CC genotype (n=4) had a 144% (P<0.001) or 61% (P=0.049) greater mean area under the plasma atorvastatin concentration-time curve from 0 to 48 h (AUC(0-48 h)) than those with the c.521TT (n=16) or c.521TC (n=12) genotype, respectively. The AUC(0-48 h) of 2-hydroxyatorvastatin was 100% greater in subjects with the c.521CC genotype than in those with the c.521TT genotype (P=0.018). Rosuvastatin AUC(0-48 h) and peak plasma concentration (Cmax) were 65% (P=0.002) and 79% (P=0.003) higher in subjects with the c.521CC genotype than in those with the c.521TT genotype. These results indicate that, unexpectedly, SLCO1B1 polymorphism has a larger effect on the AUC of atorvastatin than on the more hydrophilic rosuvastatin.

Authors+Show Affiliations

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17473846

Citation

Pasanen, M K., et al. "Different Effects of SLCO1B1 Polymorphism On the Pharmacokinetics of Atorvastatin and Rosuvastatin." Clinical Pharmacology and Therapeutics, vol. 82, no. 6, 2007, pp. 726-33.
Pasanen MK, Fredrikson H, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82(6):726-33.
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007). Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clinical Pharmacology and Therapeutics, 82(6), 726-33.
Pasanen MK, et al. Different Effects of SLCO1B1 Polymorphism On the Pharmacokinetics of Atorvastatin and Rosuvastatin. Clin Pharmacol Ther. 2007;82(6):726-33. PubMed PMID: 17473846.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. AU - Pasanen,M K, AU - Fredrikson,H, AU - Neuvonen,P J, AU - Niemi,M, Y1 - 2007/05/02/ PY - 2007/5/3/pubmed PY - 2007/12/7/medline PY - 2007/5/3/entrez SP - 726 EP - 33 JF - Clinical pharmacology and therapeutics JO - Clin Pharmacol Ther VL - 82 IS - 6 N2 - Thirty-two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1 week. Subjects with the SLCO1B1 c.521CC genotype (n=4) had a 144% (P<0.001) or 61% (P=0.049) greater mean area under the plasma atorvastatin concentration-time curve from 0 to 48 h (AUC(0-48 h)) than those with the c.521TT (n=16) or c.521TC (n=12) genotype, respectively. The AUC(0-48 h) of 2-hydroxyatorvastatin was 100% greater in subjects with the c.521CC genotype than in those with the c.521TT genotype (P=0.018). Rosuvastatin AUC(0-48 h) and peak plasma concentration (Cmax) were 65% (P=0.002) and 79% (P=0.003) higher in subjects with the c.521CC genotype than in those with the c.521TT genotype. These results indicate that, unexpectedly, SLCO1B1 polymorphism has a larger effect on the AUC of atorvastatin than on the more hydrophilic rosuvastatin. SN - 1532-6535 UR - https://www.unboundmedicine.com/medline/citation/17473846/Different_effects_of_SLCO1B1_polymorphism_on_the_pharmacokinetics_of_atorvastatin_and_rosuvastatin_ L2 - https://doi.org/10.1038/sj.clpt.6100220 DB - PRIME DP - Unbound Medicine ER -